OUTLOOK THERAPEUTICS, INC. Stock Nasdaq
Stocks
US68235M1053
Biotechnology & Medical Research
| Market Cap | 168M 147M 136M 125M 236M 16.2B 240M 1.63B 638M 7.93B 631M 617M 27.31B | P/E 2026 * |
-2.84x | P/E 2027 * | -4.63x |
|---|---|---|---|---|---|
| Enterprise Value | 168M 147M 136M 125M 236M 16.2B 240M 1.63B 638M 7.93B 631M 617M 27.31B | EV / Sales 2026 * |
140x | EV / Sales 2027 * | 3.67x |
| Free-Float |
82.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OUTLOOK THERAPEUTICS, INC.
| 1 day | -0.09% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Jahr
CEO | Chief Executive Officer | 54 | 01/07/2025 |
Lawrence Kenyon
CEO | Chief Executive Officer | 60 | 03/12/2024 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 19/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Kenyon
BRD | Director/Board Member | 60 | 02/08/2018 |
Kurt Hilzinger
BRD | Director/Board Member | 65 | 11/12/2015 |
| Chairman | 41 | 31/01/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | +11.48% | - | - | 168M | |
| -0.49% | -3.58% | -0.84% | +2.13% | 49.18B | |
| -3.10% | -0.13% | +378.16% | +584.97% | 39.58B | |
| -0.46% | +2.77% | +7.01% | +61.95% | 34.69B | |
| -1.14% | -0.97% | +29.30% | -9.20% | 34.42B | |
| -1.82% | -1.48% | +0.52% | +32.02% | 27.11B | |
| -3.54% | -4.12% | - | - | 16.21B | |
| -1.82% | +0.74% | +72.92% | +116.33% | 15.36B | |
| +1.17% | +3.10% | +15.87% | +16.79% | 14.05B | |
| -2.25% | +0.28% | +19.29% | -32.68% | 13.02B | |
| Average | -0.76% | -0.31% | +65.28% | +96.54% | 27.07B | |
| Weighted average by Cap. | -0.74% | -0.56% | +78.21% | +121.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.2M 1.05M 972K 894K 1.69M 116M 1.71M 11.63M 4.56M 56.62M 4.51M 4.41M 195M | 45.73M 40.08M 37.05M 34.07M 64.29M 4.41B 65.32M 443M 174M 2.16B 172M 168M 7.43B |
| Net income | -52.18M -45.74M -42.28M -38.88M -73.36M -5.03B -74.54M -506M -198M -2.46B -196M -192M -8.48B | -42.33M -37.1M -34.3M -31.54M -59.51M -4.08B -60.47M -410M -161M -2B -159M -155M -6.88B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
